What is Immunovant, Inc.'s R&D?

Immunovant, Inc. (IMVT) reported R&D of $142.29M in Q1 2026.

How has Immunovant, Inc.'s R&D changed year-over-year?

Immunovant, Inc.'s R&D increased by 51.9% year-over-year, from $93.65M to $142.29M.

What is the long-term trend for Immunovant, Inc.'s R&D?

Over 4 years (2022 to 2026), Immunovant, Inc.'s R&D has grown at a 45.5% compound annual growth rate (CAGR), from $101.81M to $456.66M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Immunovant, Inc. IMVT R&D

R&D at other companies

Summit TherapeuticsSMMT

$132.62M+159%

TG TherapeuticsTGTX

$48.4M+4.4%

Merck & Co.MRK

$12.59B+248%

Apogee Therapeutics, Inc.APGE

——

ImmunityBio, Inc.IBRX

——

Protagonist TherapeuticsPTGX

——

Segments

By segment

See full

Reportable Segment$29.22M-6.2%

Other financials

Income statement

See full

Net income-$147.9M-38.9%

EPS (diluted)-$0.73-15.9%

Balance sheet

See full

Cash & equivalents$902.1M+26.4%

Total debt$72.0K-26.5%

Total equity$852.6M+20.5%

Total assets$957.0M+23.3%

Cash flow

See full

Operating cash flow-$95.1M+14.1%

CapEx$8.0K-96.0%

Free cash flow-$95.1M+14.2%

Valuation

See full

Market cap$7.26B+74.2%

Enterprise value$6.35B+89.7%

Returns & leverage

See full

Return on equity-64.8%+2.5pp

Debt / equity0×0.0×

Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunovant, Inc.'s R&D?: Immunovant, Inc. (IMVT) reported R&D of $142.29M in Q1 2026.
How has Immunovant, Inc.'s R&D changed year-over-year?: Immunovant, Inc.'s R&D increased by 51.9% year-over-year, from $93.65M to $142.29M.
What is the long-term trend for Immunovant, Inc.'s R&D?: Over 4 years (2022 to 2026), Immunovant, Inc.'s R&D has grown at a 45.5% compound annual growth rate (CAGR), from $101.81M to $456.66M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.